These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38691509)

  • 41. The association between naloxone claims and proportion of independent versus chain pharmacies: A longitudinal analysis of naloxone claims in the United States.
    Freibott CE; Jalali A; Murphy SM; Walley AY; Linas BP; Jeng PJ; Bratberg J; Marshall BDL; Zang X; Green TC; Morgan JR
    J Am Pharm Assoc (2003); 2024; 64(4):102093. PubMed ID: 38604474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Naloxone Availability and Pharmacy Staff Knowledge of Standing Order for Naloxone in Pennsylvania Pharmacies.
    Graves RL; Andreyeva E; Perrone J; Shofer FS; Merchant RM; Meisel ZF
    J Addict Med; 2019; 13(4):272-278. PubMed ID: 30585876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
    Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
    Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accessibility of Naloxone in Pharmacies Registered Under the Illinois Standing Order.
    Quincy Moore P; Ellis K; Simmer P; Waetjen M; Almirol E; Salisbury-Afshar E; Pho MT
    West J Emerg Med; 2024 Jul; 25(4):457-464. PubMed ID: 39028230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
    Lozo KW; Nelson LS; Ramdin C; Calello DP
    J Med Toxicol; 2019 Apr; 15(2):108-111. PubMed ID: 30805884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
    Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
    Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
    Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
    Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
    Eldridge LA; Meyerson BE; Agley J
    J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacists' knowledge, support, and perceived roles associated with providing naloxone in the community.
    Stewart B; Thomas RL; Tutag-Lehr V
    Curr Pharm Teach Learn; 2018 Aug; 10(8):1013-1021. PubMed ID: 30314535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Point-of-sale Naloxone: Novel Community-based Research to Identify Naloxone Availability.
    Olives T; Willhite LA; Lee SC; Evans DK; Jensen A; Regelman HT; McGillis ES
    West J Emerg Med; 2020 Aug; 21(5):1188-1194. PubMed ID: 32970574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with how often community pharmacists offer and dispense naloxone.
    Carpenter DM; Dhamanaskar AK; Gallegos KL; Shepherd G; Mosley SL; Roberts CA
    Res Social Adm Pharm; 2019 Dec; 15(12):1415-1418. PubMed ID: 30007530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama.
    Hohmann L; Maxson R; McDowell L
    J Am Pharm Assoc (2003); 2023; 63(6):1731-1742.e4. PubMed ID: 37619850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
    Irwin AN; Gray M; Ventricelli D; Boggis JS; Bratberg J; Floyd AS; Silcox J; Hartung DM; Green TC
    Res Social Adm Pharm; 2024 May; 20(5):512-519. PubMed ID: 38395644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing women pharmacy consumers' experiences with weight loss treatment in Victoria and Nottingham: a cross-sectional study.
    Fakih S; Marriott JL; Boardman H; Anderson C; Hussainy SY
    BMC Public Health; 2014 Jun; 14():662. PubMed ID: 24972611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.